Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicentre, Randomized Study of Decitabine Plus GemOx Versus GemOx for Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06941688 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06941688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06941688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicentre, Randomized Study of Decitabine Plus GemOx Versus GemOx for Relapsed/Refractory Peripheral T-cell Lymphoma
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 13, 2020
Completion date
December 30, 2024
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma (ptcl)